Efficacy and Safety of Pioglitazone in a Phase 1/2 Imatinib Discontinuation Trial (EDI-PIO) in Chronic Myeloid Leukemia with Deep Molecular Response.
2020
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
6
References
2
Citations
NaN
KQI